Literature DB >> 36262357

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection.

Leonid Shmuylovich1, Aubriana M McEvoy1, Ryan C Fields2, Leonel Hernandez-Aya3, George Ansstas4, David Y Chen1.   

Abstract

Entities:  

Keywords:  HSV, herpes simplex virus; T-VEC; T-VEC, talimogene laherparepvec; disseminated herpes infection; durable response; melanoma; talimogene laherparepvec

Year:  2022        PMID： 36262357      PMCID： PMC9574543          DOI： 10.1016/j.jdcr.2022.09.012

Source DB:  PubMed          Journal:  JAAD Case Rep        ISSN： 2352-5126


× No keyword cloud information.
  10 in total

1.  Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.

Authors:  Jason Chesney; Sanjay Awasthi; Brendan Curti; Laura Hutchins; Gerald Linette; Pierre Triozzi; Marcus C B Tan; Russell E Brown; John Nemunaitis; Eric Whitman; Christopher Windham; Jose Lutzky; Gerald F Downey; Nicolas Batty; Thomas Amatruda
Journal:  Melanoma Res       Date:  2018-02       Impact factor: 3.599

Review 2.  The twilight of immunity: emerging concepts in aging of the immune system.

Authors:  Janko Nikolich-Žugich
Journal:  Nat Immunol       Date:  2017-12-14       Impact factor: 25.606

3.  Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.

Authors:  Raphael J Louie; Matthew C Perez; Mohammad Raheel Jajja; James Sun; Frances Collichio; Keith A Delman; Michael Lowe; Amod A Sarnaik; Jonathan S Zager; David W Ollila
Journal:  J Am Coll Surg       Date:  2019-01-25       Impact factor: 6.113

4.  High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).

Authors:  Viola Franke; Danique M S Berger; W Martin C Klop; Bernies van der Hiel; Bart A van de Wiel; Sylvia Ter Meulen; Michel W J M Wouters; Winan J van Houdt; Alexander C J van Akkooi
Journal:  Int J Cancer       Date:  2019-02-21       Impact factor: 7.396

5.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

6.  Disseminated Herpes Infection Following Talimogene Laherparepvec Administration.

Authors:  Brooks David Kimmis; Yen Luu; Hongyan Dai
Journal:  JAMA Dermatol       Date:  2022-04-01       Impact factor: 10.282

Review 7.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

8.  Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.

Authors:  Robert H I Andtbacka; Frances Collichio; Kevin J Harrington; Mark R Middleton; Gerald Downey; Katarina Ӧhrling; Howard L Kaufman
Journal:  J Immunother Cancer       Date:  2019-06-06       Impact factor: 13.751

9.  Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).

Authors:  Matthew C Perez; Jonathan S Zager; Thomas Amatruda; Robert Conry; Charlotte Ariyan; Anupam Desai; John M Kirkwood; Sheryl Treichel; David Cohan; Leon Raskin
Journal:  Melanoma Manag       Date:  2019-07-03

10.  Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.

Authors:  Robert H I Andtbacka; Thomas Amatruda; John Nemunaitis; Jonathan S Zager; John Walker; Jason A Chesney; Kate Liu; Cheng-Pang Hsu; Cheryl A Pickett; Janice M Mehnert
Journal:  EBioMedicine       Date:  2019-08-10       Impact factor: 8.143
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.